Biopharma | December 04, 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Subscribe To Our Newsletter & Stay Updated
